MYMD — MyMD Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapSucker Stock
- $59.99m
- $52.91m
- 41
- 15
- 30
- 17
Annual income statement for MyMD Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | R2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.35 | 1.67 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0.949 | 0.127 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 9.97 | 12.5 | 3.47 | 12.3 | 29.9 |
| Operating Profit | -6.61 | -10.8 | -3.47 | -12.3 | -29.9 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.37 | -10.8 | -3.38 | -12.2 | -29.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.37 | -10.8 | -3.38 | -12.2 | -29.9 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -7.37 | -10.8 | -3.89 | -17.6 | -29.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.37 | -10.8 | -3.89 | -17.6 | -29.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -298 | -36.8 | -10.8 | -3.45 | -0.823 |